Literature DB >> 3349601

Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy.

P Wilding1, M B Senior, T Inubushi, M L Ludwick.   

Abstract

Water-suppressed proton nuclear magnetic resonance spectra were generated (by using 360 and 500 MHz systems) from human plasma and serum samples taken from 35 apparently healthy individuals, 52 patients with overt malignancies, and 37 patients with hypertriglyceridemia (triglycerides greater than 200 mg/dL or 2.26 mmol/L). The line widths from the lipoprotein-lipid methylene and methyl resonances at approximately 1.3 and 0.9 ppm were averaged by the method of Fossel et al. (N Engl J Med 1986;315:1369-76), but, contrary to their findings, we were unable to distinguish normal individuals from those with malignant tumors (e.g., mean +/- SD line width at 360 MHz: normal group = 32.9 +/- 3.6 Hz, malignant group = 28.3 +/- 4.9 Hz). The average line-width measurements (y), however, varied with the triglyceride content (x, mg/dL) of the plasma or serum as follows (logarithmic transformation of the data determined at 360 MHz and regression analysis): y = 110 (x-0.27). Data from both nonmalignant and malignant specimens fit this equation, the coefficient of correlation being -0.91. These findings suggest that considerable caution should be used in interpreting water-suppressed proton NMR spectra for cancer detection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349601

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy.

Authors:  Mohamed I F Shariff; Jin Un Kim; Nimzing G Ladep; Asmaa I Gomaa; Mary M E Crossey; Edith Okeke; Edmund Banwat; Imam Waked; I Jane Cox; Roger Williams; Elaine Holmes; Simon D Taylor-Robinson
Journal:  J Clin Exp Hepatol       Date:  2017-03-15

2.  Nuclear magnetic resonance spectroscopy of plasma to distinguish between malignant and benign diseases causing jaundice and cholestasis.

Authors:  P A Pasanen; R Kauppinen; M J Eskelinen; K P Partanen; P H Pikkarainen; E M Alhava
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Nuclear magnetic resonance and lipids of the plasma from patients with intracranial tumours.

Authors:  S Pomeranz; E Segal; E Ashkenazi; Y Hite; S Constantini
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

4.  Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy.

Authors:  T Engan; J Krane; D C Johannessen; P E Lønning; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

5.  C-13 NMR spectroscopy of plasma reduces interference of hypertriglyceridemia in the H-1 NMR detection of malignancy. Application in patients with breast lesions.

Authors:  E T Fossel; F M Hall; J McDonagh
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

6.  Some factors that influence the plasma lipoprotein 1H NMR spectra of normal and cancer patients: an oncolipid test?

Authors:  H M Lim; T B Price; J C Marsh; P M Rainey; J C Gore; I M Armitage
Journal:  Yale J Biol Med       Date:  1991 Jan-Feb

7.  Failure to detect early breast cancer using in vitro nuclear magnetic resonance spectroscopy of plasma.

Authors:  L Holmberg; U Jakobsson; A Berglund; H O Adami
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.